A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

The primary purpose of the clinical study is to evaluate the clinical efficacy of intracranial administration of SB623 cells on patients with chronic motor deficit from Traumatic Brain Injury. A secondary purpose of the study is 1) to evaluate the effect of intracranial administration of SB623 cells on disability parameters and 2) to evaluate the safety and tolerability of intracranial administration of SB623 cells. Patients with stable, chronic motor deficits secondary to focal traumatic brain injury must be 12 months post TBI.

Start Date06 Jul 2016

Sponsor / Collaborator

SanBio, Inc.

NCT02448641 / CompletedPhase 2

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke

Start Date08 Mar 2016

Sponsor / Collaborator

SanBio, Inc.

[+1]

NCT01287936 / CompletedPhase 1/2

A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke

The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.

Start Date01 Jan 2011

Sponsor / Collaborator

SanBio, Inc.

100 Clinical Results associated with SanBio Co., Ltd.

0 Patents (Medical) associated with SanBio Co., Ltd.

Literatures (Medical) associated with SanBio Co., Ltd.

2018·Nippon Yakurigaku Zasshi

Current status of development for regenerative cell therapy, SB3623

Author: Kaneko, Takehiko

A review focuses the current status of development for regenerative cell therapy using SB3623 as regenerative medicine. SanBio Co., Ltd. is developing regenerative medicine, SB623. SB623 secretes neurotrophic and growth factors, and can possibly show benefit in repair of the damaged brain after stroke. An open-label, single-arm phase I/Ila clin. study was conducted with 18 chronic ischemic stroke patients in the United States to evaluate the safety and clin. outcomes of surgical transplantation of SB623. Clin. evaluation for a one year follow-up period showed significant improvements with all mean scores on the European Stroke Scale, the National Institute of Health Stroke Scale, and on the basis of fugl-Meyer Assessment. All patients experienced neither side effects nor serious treatment-emergent adverse events related to cell treatments. These results suggest that SB623 cell transplantation is safe and effective for treating chronic ischemic stroke. Currently, we are conducting clin. studies in Japan and the US, and are accelerating clin. development to provide our cells to patients under new regulation of regenerative medical products in Japan.

30 Sep 2017·BIO Clinica

Current status of SB623 development for central nervous system

Author: Kaneko, Takehiko

The paper presents the current status of SB623 development for central nervous system. It states that there were no side effects or serious adverse events, it has the function of secreting neurotrophic factors and growth factors, and can contribute to the repair of brain nerve function. Finally, the results suggest that SB623 is safe and effective against chronic cerebral infarction.

18 Feb 2017·Igaku no Ayumi

Current status of clinical development in a Japanese bio-venture, SanBio

Author: Kaneko, Takehiko ; Furukawa, Takashi

The present paper describes on the endogenous neural stem cells survive in the brain for a long time after the disappearance of SB623 and repair the damage, suggesting that SB623 transplantation promotes intrinsic self-renewal in the damaged brain, through these mechanisms, SB623 is thought to be involved in repair after brain injury.

News (Medical) associated with SanBio Co., Ltd.

28 Nov 2022

·www.prnewswire.com

Acute Ischemic Stroke Therapeutics Market: Growth Opportunities led by Athersys Inc. and Bayer AG - Technavio

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- The acute ischemic stroke (AIS) therapeutics market size is estimated to grow by USD 1,524.49 million during 2022-2027, at a CAGR of 5.72%. The growth of the market will be driven by the rising prevalence of high-risk factors. Furthermore, the use of technologies such as TBI is expected to boost market growth. Continue Reading Technavio has announced its latest market research report titled Global Acute Ischemic Stroke Therapeutics Market 2023-2027 The report extensively covers the acute ischemic stroke (AIS) therapeutics market segmentation by type (thrombolytic, anticoagulants, antiplatelets, and antihypertensives), distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW). Request a Free Sample Report Acute Ischemic Stroke Therapeutics Market - Vendors The global AIS therapeutics market is a fragmented market, with the presence of various large and small players. Large players are focusing on consolidating the market through increased strategic alliances and acquisitions to increase their market shares. In addition, these vendors are continuously innovating their offerings. Some of the key vendors are listed below: Athersys Inc. Bayer AG Biogen Inc. Boehringer Ingelheim International GmbH Medtronic Plc NoNO Inc. SanBio Co Ltd. Stryker Corp. Amgen Inc. AstraZeneca Plc Bristol Myers Squibb Co. Daiichi Sankyo Co. Ltd. F. Hoffmann La Roche Ltd. Johnson & Johnson Merck & Co. Inc. Sanofi SA Teva Pharmaceutical Industries Ltd. Product Insights and News • athersys.com: The company offers acute ischemic stroke therapeutics such as Repatha. • bayer.com - The company offers acute ischemic stroke therapeutics such as BRILINTA ticagrelor tablets. • biogen.com - The company offers acute ischemic stroke therapeutics such as Masters 2 MultiStem cell therapy. For detailed insights about product offerings and the growth strategies adopted by vendors, buy the report. Acute Ischemic Stroke Therapeutics Market - Geographical Landscape North America is estimated to account for 38% of the market's growth during the forecast period. The growth of the market in this region is attributed to factors such as the expected approval of late-stage pipeline molecules, including BIIB093 (intravenous glibenclamide), BRILINTA, MultiStem, and NA-1. In addition, the region is expected to witness the availability of various diagnostics and drugs for the treatment of stroke, which will drive market growth. Acute Ischemic Stroke Therapeutics Market - Market Segmentation The thrombolytics segment is estimated to contribute the highest share of the global market's growth during the forecast period. One of the factors behind the growth of this segment is the availability of US FDA-approved therapeutic treatments for AIS. For instance, the IV alteplase drug is sold under the brand name Activase. It is a tissue plasminogen activator and is used for multiple indications such as AIS, acute myocardial infarction (AMI), and acute massive pulmonary embolism (PE). Download a free sample report What are the key data covered in this acute ischemic stroke (AIS) therapeutics market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the acute ischemic stroke (AIS) therapeutics market between 2023 and 2027 Precise estimation of the size of the acute ischemic stroke (AIS) therapeutics market size and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the acute ischemic stroke (AIS) therapeutics market across APAC, North America, Europe, Middle East and Africa, and South America Thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of acute ischemic stroke (AIS) therapeutics market vendors Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights Related Reports: APAC Acute Myeloid Leukemia (AML) Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The acute myeloid leukemia (AML) treatment market size in APAC is projected to grow by USD 277.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.83%. Alzheimer's Disease Therapeutics Market by Drug Class and Geography - Forecast and Analysis 2022-2026: The Alzheimer's disease therapeutics market size is projected to grow by USD 3.99 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.76%. Browse for Technavio " Health Care " Research Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 18: Five forces analysis - Comparison between 2022 and 2027 4.2 Bargaining power of buyers Exhibit 19: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 4.3 Bargaining power of suppliers Exhibit 20: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 4.4 Threat of new entrants Exhibit 21: Threat of new entrants – Impact of key factors in 2022 and 2027 4.5 Threat of substitutes Exhibit 22: Threat of substitutes – Impact of key factors in 2022 and 2027 4.6 Threat of rivalry Exhibit 23: Threat of rivalry – Impact of key factors in 2022 and 2027 4.7 Market condition Exhibit 24: Chart on Market condition - Five forces 2022 and 2027 5 Market Segmentation by Type 5.1 Market segments Exhibit 25: Chart on Type - Market share 2022-2027 (%) Exhibit 26: Data Table on Type - Market share 2022-2027 (%) 5.2 Comparison by Type Exhibit 27: Chart on Comparison by Type Exhibit 28: Data Table on Comparison by Type 5.3 Thrombolytics - Market size and forecast 2022-2027 Exhibit 29: Chart on Thrombolytics - Market size and forecast 2022-2027 ($ million) Exhibit 30: Data Table on Thrombolytics - Market size and forecast 2022-2027 ($ million) Exhibit 31: Chart on Thrombolytics - Year-over-year growth 2022-2027 (%) Exhibit 32: Data Table on Thrombolytics - Year-over-year growth 2022-2027 (%) 5.4 Anticoagulants - Market size and forecast 2022-2027 Exhibit 33: Chart on Anticoagulants - Market size and forecast 2022-2027 ($ million) Exhibit 34: Data Table on Anticoagulants - Market size and forecast 2022-2027 ($ million) Exhibit 35: Chart on Anticoagulants - Year-over-year growth 2022-2027 (%) Exhibit 36: Data Table on Anticoagulants - Year-over-year growth 2022-2027 (%) 5.5 Antiplatelets - Market size and forecast 2022-2027 Exhibit 37: Chart on Antiplatelets - Market size and forecast 2022-2027 ($ million) Exhibit 38: Data Table on Antiplatelets - Market size and forecast 2022-2027 ($ million) Exhibit 39: Chart on Antiplatelets - Year-over-year growth 2022-2027 (%) Exhibit 40: Data Table on Antiplatelets - Year-over-year growth 2022-2027 (%) 5.6 Antihypertensives - Market size and forecast 2022-2027 Exhibit 41: Chart on Antihypertensives - Market size and forecast 2022-2027 ($ million) Exhibit 42: Data Table on Antihypertensives - Market size and forecast 2022-2027 ($ million) Exhibit 43: Chart on Antihypertensives - Year-over-year growth 2022-2027 (%) Exhibit 44: Data Table on Antihypertensives - Year-over-year growth 2022-2027 (%) 5.7 Other therapeutics - Market size and forecast 2022-2027 Exhibit 45: Chart on Other therapeutics - Market size and forecast 2022-2027 ($ million) Exhibit 46: Data Table on Other therapeutics - Market size and forecast 2022-2027 ($ million) Exhibit 47: Chart on Other therapeutics - Year-over-year growth 2022-2027 (%) Exhibit 48: Data Table on Other therapeutics - Year-over-year growth 2022-2027 (%) 5.8 Market opportunity by Type Exhibit 49: Market opportunity by Type ($ million) 6 Market Segmentation by Distribution Channel 6.1 Market segments Exhibit 50: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibit 51: Data Table on Distribution Channel - Market share 2022-2027 (%) 6.2 Comparison by Distribution Channel Exhibit 52: Chart on Comparison by Distribution Channel Exhibit 53: Data Table on Comparison by Distribution Channel 6.3 Hospital pharmacies - Market size and forecast 2022-2027 Exhibit 54: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) Exhibit 55: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million) Exhibit 56: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%) Exhibit 57: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%) 6.4 Retail pharmacies - Market size and forecast 2022-2027 Exhibit 58: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million) Exhibit 59: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million) Exhibit 60: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%) Exhibit 61: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%) 6.5 Online pharmacies - Market size and forecast 2022-2027 Exhibit 62: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million) Exhibit 63: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million) Exhibit 64: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%) Exhibit 65: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%) 6.6 Market opportunity by Distribution Channel Exhibit 66: Market opportunity by Distribution Channel ($ million) 7 Customer Landscape 7.1 Customer landscape overview Exhibit 67: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 8 Geographic Landscape 8.1 Geographic segmentation Exhibit 68: Chart on Market share by geography 2022-2027 (%) Exhibit 69: Data Table on Market share by geography 2022-2027 (%) 8.2 Geographic comparison Exhibit 70: Chart on Geographic comparison Exhibit 71: Data Table on Geographic comparison 8.3 North America - Market size and forecast 2022-2027 Exhibit 72: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 73: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 74: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 75: Data Table on North America - Year-over-year growth 2022-2027 (%) 8.4 Europe - Market size and forecast 2022-2027 Exhibit 76: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 77: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 78: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 79: Data Table on Europe - Year-over-year growth 2022-2027 (%) 8.5 Asia - Market size and forecast 2022-2027 Exhibit 80: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 81: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 82: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 83: Data Table on Asia - Year-over-year growth 2022-2027 (%) 8.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 84: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 85: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 86: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 87: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 8.7 US - Market size and forecast 2022-2027 Exhibit 88: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 89: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 90: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 91: Data Table on US - Year-over-year growth 2022-2027 (%) 8.8 UK - Market size and forecast 2022-2027 Exhibit 92: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 93: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 94: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 95: Data Table on UK - Year-over-year growth 2022-2027 (%) 8.9 Germany - Market size and forecast 2022-2027 Exhibit 96: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 97: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 98: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 99: Data Table on Germany - Year-over-year growth 2022-2027 (%) 8.10 China - Market size and forecast 2022-2027 Exhibit 100: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 101: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 102: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 103: Data Table on China - Year-over-year growth 2022-2027 (%) 8.11 Canada - Market size and forecast 2022-2027 Exhibit 104: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibit 105: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibit 106: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibit 107: Data Table on Canada - Year-over-year growth 2022-2027 (%) 8.12 Market opportunity by geography Exhibit 108: Market opportunity by geography ($ million) 9 Drivers, Challenges, and Trends 9.1 Market drivers 9.2 Market challenges 9.3 Impact of drivers and challenges Exhibit 109: Impact of drivers and challenges in 2022 and 2027 9.4 Market trends 10 Vendor Landscape 10.1 Overview 10.2 Vendor landscape Exhibit 110: Overview on Criticality of inputs and Factors of differentiation 10.3 Landscape disruption Exhibit 111: Overview on factors of disruption 10.4 Industry risks Exhibit 112: Impact of key risks on business 11 Vendor Analysis 11.1 Vendors covered Exhibit 113: Vendors covered 11.2 Market positioning of vendors Exhibit 114: Matrix on vendor position and classification 11.3 Amgen Inc. Exhibit 115: Amgen Inc. - Overview Exhibit 116: Amgen Inc. - Product / Service Exhibit 117: Amgen Inc. - Key offerings 11.4 AstraZeneca Plc Exhibit 118: AstraZeneca Plc - Overview Exhibit 119: AstraZeneca Plc - Product / Service Exhibit 120: AstraZeneca Plc - Key news Exhibit 121: AstraZeneca Plc - Key offerings 11.5 Athersys Inc. Exhibit 122: Athersys Inc. - Overview Exhibit 123: Athersys Inc. - Product / Service Exhibit 124: Athersys Inc. - Key offerings 11.6 Bayer AG Exhibit 125: Bayer AG - Overview Exhibit 126: Bayer AG - Business segments Exhibit 127: Bayer AG - Key offerings Exhibit 128: Bayer AG - Segment focus 11.7 Biogen Inc. Exhibit 129: Biogen Inc. - Overview Exhibit 130: Biogen Inc. - Product / Service Exhibit 131: Biogen Inc. - Key offerings 11.8 Boehringer Ingelheim International GmbH Exhibit 132: Boehringer Ingelheim International GmbH - Overview Exhibit 133: Boehringer Ingelheim International GmbH - Business segments Exhibit 134: Boehringer Ingelheim International GmbH - Key news Exhibit 135: Boehringer Ingelheim International GmbH - Key offerings Exhibit 136: Boehringer Ingelheim International GmbH - Segment focus 11.9 Bristol Myers Squibb Co. Exhibit 137: Bristol Myers Squibb Co. - Overview Exhibit 138: Bristol Myers Squibb Co. - Product / Service Exhibit 139: Bristol Myers Squibb Co. - Key offerings 11.10 Daiichi Sankyo Co. Ltd. Exhibit 140: Daiichi Sankyo Co. Ltd. - Overview Exhibit 141: Daiichi Sankyo Co. Ltd. - Business segments Exhibit 142: Daiichi Sankyo Co. Ltd. - Key news Exhibit 143: Daiichi Sankyo Co. Ltd. - Key offerings Exhibit 144: Daiichi Sankyo Co. Ltd. - Segment focus 11.11 F. Hoffmann La Roche Ltd. Exhibit 145: F. Hoffmann La Roche Ltd. - Overview Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments Exhibit 147: F. Hoffmann La Roche Ltd. - Key news Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus 11.12 Johnson and Johnson Exhibit 150: Johnson and Johnson - Overview Exhibit 151: Johnson and Johnson - Business segments Exhibit 152: Johnson and Johnson - Key news Exhibit 153: Johnson and Johnson - Key offerings Exhibit 154: Johnson and Johnson - Segment focus 11.13 Medtronic Plc Exhibit 155: Medtronic Plc - Overview Exhibit 156: Medtronic Plc - Business segments Exhibit 157: Medtronic Plc - Key news Exhibit 158: Medtronic Plc - Key offerings Exhibit 159: Medtronic Plc - Segment focus 11.14 Merck and Co. Inc. Exhibit 160: Merck and Co. Inc. - Overview Exhibit 161: Merck and Co. Inc. - Business segments Exhibit 162: Merck and Co. Inc. - Key news Exhibit 163: Merck and Co. Inc. - Key offerings Exhibit 164: Merck and Co. Inc. - Segment focus 11.15 Pfizer Inc. Exhibit 165: Pfizer Inc. - Overview Exhibit 166: Pfizer Inc. - Product / Service Exhibit 167: Pfizer Inc. - Key news Exhibit 168: Pfizer Inc. - Key offerings 11.16 Sanofi SA Exhibit 169: Sanofi SA - Overview Exhibit 170: Sanofi SA - Business segments Exhibit 171: Sanofi SA - Key news Exhibit 172: Sanofi SA - Key offerings Exhibit 173: Sanofi SA - Segment focus 11.17 Teva Pharmaceutical Industries Ltd. Exhibit 174: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 175: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key news Exhibit 177: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 178: Teva Pharmaceutical Industries Ltd. - Segment focus 12 Appendix 12.1 Scope of the report 12.2 Inclusions and exclusions checklist Exhibit 179: Inclusions checklist Exhibit 180: Exclusions checklist 12.3 Currency conversion rates for US$ Exhibit 181: Currency conversion rates for US$ 12.4 Research methodology Exhibit 182: Research methodology Exhibit 183: Validation techniques employed for market sizing Exhibit 184: Information sources 12.5 List of abbreviations Exhibit 185: List of abbreviations About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Acquisition

100 Deals associated with SanBio Co., Ltd.

100 Translational Medicine associated with SanBio Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 05 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Vandefitemcel ( NGF )	Stroke More	Phase 2
MSC2	Inflammation More	Preclinical
SB618	Neuropathy More	Preclinical
SB308	Muscular Dystrophies More	Discovery
MSC1	Neoplasms More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis